Samuel Phillips1, Suzanne M Garland2, Jeffery H Tan3, Michael A Quinn3, Sepehr N Tabrizi4. 1. Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia; Murdoch Childrens Research Institute, Parkville, Victoria 3052, Australia. 2. Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia; Murdoch Childrens Research Institute, Parkville, Victoria 3052, Australia. 3. Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia; Oncology and Dysplasia Unit, Royal Women's Hospital, Parkville, Victoria, Australia. 4. Regional HPV Lab Net Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia; Murdoch Childrens Research Institute, Parkville, Victoria 3052, Australia. Electronic address: sepehr.tabrizi@thewomens.org.au.
Abstract
BACKGROUND: The recently FDA (U.S. food and drug administration) approved Roche Cobas(®) 4800 (Cobas) human papillomavirus (HPV) has limited performance data compared to current HPV detection methods for test of cure in women undergoing treatment for high grade lesions. OBJECTIVE: Evaluation of Cobas HPV assay using historical samples from women undergoing treatment for cervical dysplasia. STUDY DESIGN: A selection of 407 samples was tested on the Cobas assay and compared to previous results from Hybrid Capture 2, HPV Amplicor and Roche Linear Array. RESULTS: Overall, a correlation between high-risk HPV positivity and high grade histological diagnosis was 90.6% by the Cobas, 86.1% by Hybrid Capture 2, 92.9% by HPV Amplicor and 91.8% by Roche Linear Array. CONCLUSION: The Cobas HPV assay is comparative to both the HPV Amplicor and Roche Linear Array assays and better than Hybrid capture 2 assay in the detection of High-Risk HPV in women undergoing treatment for cervical dysplasia.
BACKGROUND: The recently FDA (U.S. food and drug administration) approved Roche Cobas(®) 4800 (Cobas) human papillomavirus (HPV) has limited performance data compared to current HPV detection methods for test of cure in women undergoing treatment for high grade lesions. OBJECTIVE: Evaluation of CobasHPV assay using historical samples from women undergoing treatment for cervical dysplasia. STUDY DESIGN: A selection of 407 samples was tested on the Cobas assay and compared to previous results from Hybrid Capture 2, HPV Amplicor and Roche Linear Array. RESULTS: Overall, a correlation between high-risk HPV positivity and high grade histological diagnosis was 90.6% by the Cobas, 86.1% by Hybrid Capture 2, 92.9% by HPV Amplicor and 91.8% by Roche Linear Array. CONCLUSION: The CobasHPV assay is comparative to both the HPV Amplicor and Roche Linear Array assays and better than Hybrid capture 2 assay in the detection of High-Risk HPV in women undergoing treatment for cervical dysplasia.
Authors: A M Cornall; M Poljak; S M Garland; S Phillips; J H Tan; D A Machalek; M A Quinn; S N Tabrizi Journal: Eur J Clin Microbiol Infect Dis Date: 2016-11-08 Impact factor: 3.267
Authors: S Phillips; A M Cornall; D A Machalek; S M Garland; D Bateson; M Garefalakis; S N Tabrizi Journal: Eur J Clin Microbiol Infect Dis Date: 2016-05-13 Impact factor: 3.267
Authors: Rayleen M Lewis; Allison L Naleway; Nicola P Klein; Bradley Crane; Amber Hsiao; Laurie Aukes; Julius Timbol; Troy D Querec; Martin Steinau; Sheila Weinmann; Elizabeth R Unger; Lauri E Markowitz Journal: J Low Genit Tract Dis Date: 2022-04-01 Impact factor: 3.842
Authors: A M Cornall; M Poljak; S M Garland; S Phillips; D A Machalek; J H Tan; M A Quinn; S N Tabrizi Journal: Eur J Clin Microbiol Infect Dis Date: 2016-04-05 Impact factor: 3.267
Authors: Alyssa M Cornall; Marin Poljak; Suzanne M Garland; Samuel Phillips; Dorothy A Machalek; Jeffrey H Tan; Michael A Quinn; Sepehr N Tabrizi Journal: Papillomavirus Res Date: 2017-10-18